A phase 3 trial shows that ditching chemotherapy in favor of ponatinib plus blinatumomab significantly boosts survival in adults with Philadelphia-positive acute lymphoblastic leukemia. The chemo-free regimen delivered a 24-month event-free survival rate of 86%, compared to just 67% with the standard imatinib-plus-chemo approach. Fewer severe side effects were also reported in the chemo-free group.
A chemotherapy-free frontline regimen is making a strong case for reshaping how doctors treat Philadelphia-positive acute lymphoblastic leukemia (Ph-positive ALL). Results from the phase 3 GIMEMA ALL2820 trial, published in The New England Journal of Medicine, show that combining ponatinib with blinatumomab significantly outperforms the standard imatinib-plus-chemotherapy approach in adult patients.
The trial enrolled 236 adults with Ph-positive ALL, randomizing them to either the chemo-free combo (ponatinib + blinatumomab) or the conventional regimen (imatinib + chemotherapy). After a median follow-up of nearly two years, the chemo-free group showed markedly better outcomes across multiple measures — and with a more favorable safety profile.
By the Numbers:
Why it matters: This trial formally proves that a targeted, immunotherapy-based strategy can surpass conventional chemotherapy in Ph-positive ALL — a significant step toward reducing the toxic burden of treatment while improving patient outcomes.
